The administration of dexamethasone to critical COVID-19 patients was found to significantly reduce the plasma levels of inflammatory mediators including IL-1β, IL-6, IL-8, IL-10, and MIP-1α, and this to counteracted hyper-inflammation [154]. This evidence concerns the gene CXCL8 and COVID-19.